Patents by Inventor John Gerard Ward

John Gerard Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxyethylene compounds with Asp2 inhibitory activity
    Patent number: 7160905
    Abstract: The present invention relates to novel hydroxyethylene compounds having Asp2 (?-secretase. BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated ?-amyloid levels or ?-amyloid deposits, particularly Alzheimer's disease.
    Type: Grant
    Filed: November 29, 2002
    Date of Patent: January 9, 2007
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Andrew Faller, Peter Henry Milner, John Gerard Ward
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Publication number: 20040077727
    Abstract: A compound of formula (I) wherein: R is isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Application
    Filed: October 3, 2003
    Publication date: April 22, 2004
    Applicant: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Patent number: 6673965
    Abstract: A compound of formula (I) wherein: R isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: January 6, 2004
    Assignee: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller